Persistence of immunity in children immunised with 13-valent pneumococcal conjugate vaccine and impact on nasopharyngeal carriage: a cross-sectional study.
bacterial infection
clinical epidemiology
infection control
paediatric lung disaese
pneumonia
respiratory infection
Journal
Thorax
ISSN: 1468-3296
Titre abrégé: Thorax
Pays: England
ID NLM: 0417353
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
26
07
2019
revised:
16
04
2020
accepted:
17
04
2020
pubmed:
24
5
2020
medline:
21
8
2020
entrez:
24
5
2020
Statut:
ppublish
Résumé
In 500 children aged ≤10 years after 13-valent pneumococcal conjugate vaccine (PCV)13 immunisation in different schedules, serotypes 19A-specific and 19F-specific immunoglobulin G (IgG) were predicted to persist above 0.35 µg/mL for ≥10 years in all groups, likely due to PCV13-induced memory with natural boosting from residual diseases and colonisation. Generally, serotype-specific IgG could persist above 0.35 µg/mL longer (≥5 years) in the catch-up group than in the 2+1 and 3+1 immunisation groups. 14.5% of the carriage isolates belonged to PCV13 serotypes; statistical analysis revealed that a high serum IgG level (>10.96 µg/mL) will be required to eliminate the point-prevalence nasopharyngeal carriage of serotype 19A.
Identifiants
pubmed: 32444435
pii: thoraxjnl-2019-213878
doi: 10.1136/thoraxjnl-2019-213878
pmc: PMC7402562
doi:
Substances chimiques
13-valent pneumococcal vaccine
0
Pneumococcal Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
689-692Informations de copyright
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Pediatr Infect Dis J. 2011 Dec;30(12):1086-91
pubmed: 21983216
Clin Infect Dis. 2019 Oct 15;69(9):1581-1587
pubmed: 30923808
Clin Vaccine Immunol. 2013 Jul;20(7):1034-40
pubmed: 23658394
PLoS One. 2014 Mar 11;9(3):e91413
pubmed: 24618837
Vaccine. 2016 Aug 5;34(36):4313-20
pubmed: 27422342
Sci Rep. 2015 Nov 02;5:15843
pubmed: 26522920
Lancet Infect Dis. 2018 Feb;18(2):171-179
pubmed: 29174323
Lancet Infect Dis. 2014 Sep;14(9):839-46
pubmed: 25042756
Vaccine. 2012 Mar 9;30(12):2054-9
pubmed: 22198517
Am J Respir Crit Care Med. 2016 Dec 15;194(12):1523-1531
pubmed: 27403678
Clin Infect Dis. 2018 Jul 18;67(3):367-374
pubmed: 29471432
J Microbiol Immunol Infect. 2018 Apr;51(2):199-206
pubmed: 29021105